Hemophilia A and B involve deficiencies in coagulation factors VIII and IX, with traditional treatments requiring frequent infusions. Nonfactor therapies, including Hemlibra and rebalancing agents, ...
A study suggests twice-yearly Yeztugo offers HIV prevention without adversely affecting gender-affirming care.
Mrs Gifty Addo-Tetebo, Eastern Regional Coordinator for STI /HIV and AIDS at the Regional Health Directorate, has entreated ...
Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field studyExpect to ...
New York has passed several new laws taking effect in January and February, including requirements for doctors and hospitals ...
Thirteen people who were in direct contact with the rabid dog have started post-exposure treatment and had not displayed any ...
Trodelvy showed fewer severe side effects, such as neutropenia and diarrhea, compared to chemotherapy in untreated TNBC ...
Pfizer disclosed a patient death in a marstacimab hemophilia study, triggering a safety review and reassessment of surgical ...
DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID ...
Background The likelihood of HIV acquisition is increased following forced vaginal sex. This relates in part to ...
Surgical antimicrobial prophylaxis using non-beta‑lactams administered before major surgery was independently associated with a significantly higher risk for surgical site infection than conventional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback